Shares of Biogen fell about 3% in afternoon trading. The Cambridge, Mass.-based biopharmaceutical company is facing a patent challenge from Mylan for its top-selling drug,...
Pittsburgh, Nov. 14, 2019 (GLOBE NEWSWIRE) -- UPMC Health Plan announced today that it has entered into a value-based agreement with Biogen for Tecfidera® (dimethyl fumarate) and...
Source: gopixa / iStockStocks were mixed in the premarket on Tuesday and the day was just looking for direction after last week’s all-time highs. Investors still have a lot of...
Wall Street has gaining on optimism surrounding the signing of a "phase one" trade deal between the United States and China. The S&P 500, in fact, crossed the 3,100 mark this...
It was a busy week for the biotech sector with updates from quite a few companies. Solid Biosciences (NASDAQ:SLDB) plummeted after the FDA placed a clinical hold on its gene...
Roche (OTC:RHHBY) announced positive data from the part 2 of the SUNFISH study on pipeline candidate, risdiplam, in patients with spinal muscular atrophy (SMA).Risdiplam is an...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Technical Indicators||Strong Buy||Strong Buy||Strong Buy||Strong Sell||Sell|
|Summary||Strong Buy||Strong Buy||Strong Buy||Neutral||Neutral|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Outside Down||1D||2||Nov 13, 2019|
|Engulfing Bearish||1M||3||Aug 19|
|Evening Doji Star||1M||3||Aug 19|
|Falling Three Methods||1M||3||Aug 19|
|Engulfing Bearish||1D||3||Nov 12, 2019|
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.Read More
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.